Related Experiment Video
Updated: Aug 16, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
[Autoimmune neuropathies--current aspects of immunopathologic diagnostics and therapy]
1Institut für Multiple-Sklerose-Forschung, Bereich Humanmedizin der Universität Göttingen und Gemeinnützige Hertie-Stiftung, .
Der Nervenarzt
|August 5, 2005
Summary
This review covers autoimmune neuropathies like Guillain-Barré syndrome. It details diagnostic strategies and discusses various immunotherapies, noting their lack of specificity and unclear mechanisms.
Area of Science:
- Neurology
- Immunology
- Pathology
Context:
- Autoimmune neuropathies encompass a range of debilitating conditions.
- Accurate diagnosis is crucial for effective management.
- Current treatments lack specificity and have unclear mechanisms.
Purpose:
- To outline diagnostic pathways for autoimmune neuropathies.
- To review current and long-term immunotherapies.
- To highlight considerations for modern immunotherapy.
Summary:
- Key autoimmune neuropathies include Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuritis, multifocal motor neuropathy, and vasculitic neuropathies.
- Diagnostic strategies aim for rational decision-making.
- Acute treatments involve glucocorticosteroids, plasmapheresis, and IVIg; long-term options include azathioprine, cyclosporine, cyclophosphamide, and immunoglobulins.
Impact:
- Facilitates informed diagnostic decisions in immune neuropathies.
- Provides an overview of therapeutic options for clinicians.
- Emphasizes the need to consider medical, evidence-based, and economic factors in immunotherapy.
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...